Source Fact: Eugene Investment & Securities / Published on June 29, 2026
Investment Opinion & Target Price: NR (Not Rated / Maintaining No Rating or Target Price)
Key Momentum: Projected H2 earnings recovery driven by expanding OIS/eOIS Driver IC supply volumes to core domestic and Chinese clients, alongside the Ministry of Food and Drug Safety (MFDS) Investigational New Drug (IND) approval track for the ‘D-SaLife’ salivary glucose monitoring system and its subsequent global Licensing-Out (L/O) pipeline.
📊 1. [Section Title: Valuation Indicators and Investment Metrics Analysis]
- Investment Rating & Valuation Status: Maintaining an NR (Not Rated) designation for Dongwoon Anatech (094170.KQ). Based on estimated 2026 earnings, the stock trades at a Price-to-Earnings (P/E) multiple of 62.6x, representing a clear valuation premium compared to the domestic peer group average of 38.6x. The structural turnaround of its core H2 IT business and the tangible regulatory progress of its medical device pipeline serve as the primary catalysts to justify this premium and drive further upside.
- Annual Earnings Forecast Trajectory (2026F): For the full year of 2026, consolidated annual revenue is projected at 128.0 billion KRW, operating profit at 1.5 billion KRW, and net income at 10.0 billion KRW. While top-line revenue is set to tick up slightly compared to the prior year (2025A Revenue: 127.6 billion KRW, Operating Profit: 2.4 billion KRW), full-year operating profit is forecast to moderate slightly due to weak first-half underperformance.
- Key Financial & Profitability Ratios: The estimated Return on Equity (ROE) for 2026 is forecast to improve to 13.8%, while the Price-to-Book (P/B) ratio tracks at 8.3x and EV/EBITDA at 156.4x, reflecting elevated valuation multiples.
- 2Q26 Quarterly Earnings Preview: Second-quarter consolidated revenue is projected to decline 12.3% YoY to 26.4 billion KRW, with an operating loss estimated at 2.1 billion KRW, indicating a continued deficit trailing from the previous quarter. This structural drag stems directly from lower OIS (Optical Image Stabilization) Driver IC billings amid prolonged sales slumps at its primary Chinese client.
🚀 2. [Section Title: Total Addressable Market (TAM) & Detailed Earnings Forecasts]
- H2 IT Division Turnaround Visibility: While first-half operations faced heavy friction due to the Chinese client slowdown—triggering an 18.3% YoY drop in OIS revenue—the downside was firmly anchored by a 16.0% YoY expansion in AF (Auto Focus) Driver IC sales. Moving into the second half, top-line performance is poised to shift back into a expansionary cycle, driven by scaling eOIS Driver IC shipments to core domestic clients and expanding procurement orders from China.
- Salivary Glucose Monitoring System ‘D-SaLife’ MFDS Approval Pipeline:
- IND Submission Timeline: In accordance with the newly implemented ‘Digital Medical Products Act,’ regulatory filings will categorize the system as a ‘digital medical device embedded with AI technology software’. The company is positioned to officially submit its formal IND (Investigational New Drug) clinical trial application immediately upon securing its ‘Clinical GMP Compliance Certificate’ in July.
- Clinical Trials & Commercial Targets: Following IND approval, the company will initiate a confirmatory clinical study covering approximately 100 multi-ethnic participants over a two-month period, targeting a formal domestic commercial rollout and product launch by 2027.
- Global Clinical Data Generation and L/O Strategy:
- Multi-ethnic pilot clinical trial data currently being generated through parallel studies at the UCLA School of Dentistry and Seoul National University Dental Hospital will be unveiled to the scientific community for the first time as a peer-reviewed paper at the 1st ASGRS (International Society for Salivary Gland Research) International Symposium, held at Yonsei University on September 3–4, 2026.
- Leveraging this multi-ethnic clinical foundation, the company is actively collaborating with global investment banks (IBs) and healthcare specialized brokerages to clear overseas regulatory frameworks, aiming to establish a recurring royalty business architecture via licensing-out (L/O) agreements with global pharmaceutical firms.
📝 Editor’s Comment (by K-STOCK Editor)
Dongwoon Anatech is currently trading at a stretched forward multiple of 62.6x P/E, a distinct premium relative to its immediate peer group. This valuation premium reflects the market’s willingness to look past near-term first-half earnings headwinds in China, opting instead to price in a substantial digital healthcare options value for the ‘D-SaLife’ salivary glucose monitoring system. From a technical standpoint, the receipt of the Clinical GMP certification and the subsequent MFDS IND filing in July will represent critical operational milestones, transitioning the project from a speculative R&D endeavor into a structured commercial pipeline. Furthermore, the multi-ethnic pilot clinical dataset to be introduced at the upcoming ASGRS International Symposium in early September will serve as the core pivot point determining the ultimate valuation of any future global big pharma licensing deals. If the core IT business successfully snaps its deficit streak in the second half via domestic eOIS volume scaling, and the regulatory pathway for its digital medical device gains visible velocity, the stock’s elevated multiple can be fully justified as long-term growth momentum.
📢 Disclaimer & Source Information
- Source: This content has been newly structured and written based on publicly disclosed financial facts and numerical data extracted from brokerage research reports
- Investment Risk Warning: This material is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the individual investor.
- Contact: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
